Weiss Ratings Reiterates Sell (D-) Rating for MediWound (NASDAQ:MDWD)

Key Points

• Weiss Ratings has reiterated a sell (D-) rating for MediWound (NASDAQ:MDWD), indicating ongoing concerns about the company's stock performance.
• The company's recent quarterly earnings report showed a significant earnings per share miss, with a reported (1.23) EPS compared to estimates of (0.55).
• MediWound's stock has a consensus rating of Moderate Buy from analysts, with a target price of $32.25.

MediWound (NASDAQ:MDWD - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Other equities research analysts have also recently issued reports about the stock. Zacks Research cut shares of MediWound from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Wall Street Zen cut shares of MediWound from a "hold" rating to a "sell" rating in a report on Friday, July 18th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

MediWound Price Performance

MediWound stock opened at $17.63 on Wednesday. The firm has a 50-day moving average of $17.61 and a 200-day moving average of $18.45. MediWound has a one year low of $14.14 and a one year high of $22.50. The company has a market cap of $195.46 million, a price-to-earnings ratio of -6.68 and a beta of 0.27.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.68). MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%.The business had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. As a group, sell-side analysts expect that MediWound will post -2.66 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in shares of MediWound by 1,507.1% during the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,703 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 649 shares during the period. Corebridge Financial Inc. increased its holdings in shares of MediWound by 17.1% during the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 665 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after acquiring an additional 999 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of MediWound by 2,255.2% during the 1st quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 6,044 shares in the last quarter. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.